Original

Optimization of Tablet Formulation using Artificial Neural Networks and Genetic Algorithm

Kisanrao Bibhishan Mundhe[1], Dr. Chitra V[2], Dr. Parani Madasamy[3]

[1]Research Scholar, College of Pharmacy, SRM University.
[2]Dean, Professor & Head, Department of Pharmacology, College of Pharmacy, SRM University.
[3]Professor and Chairperson (School of Bio Engineering) SRM University.

Abstract
The several elements influencing final product quality make pharmaceutical tablet formulation optimization still a difficult task. This paper investigates a novel method to simplify and improve tablet formulation development using artificial neural networks (ANNs) with genetic algorithms (GA). The work trained ANNs capable of predicting correlations between formulation factors (excipient kinds, concentrations, processing parameters) and critical quality attributes (dissolution rate, hardness, friability) using experimental data from many formulations. Within a GA framework, the trained neural network acted as a predictive model effectively searching the formulation design space for best solutions. By means of this combination technique, formulation parameters producing tablets with exceptional properties were effectively identified while optimizing development time and resources. Excellent match between expected and experimental results shown by the optimized formulations confirmed the potency of the model. Moreover, sensitivity analysis exposed the relative significance of every formulation factor, thereby offering insightful information on formulation mechanics. With reduced experimental burden and expedited time-to----market for novel drug products, this ANN-GA hybrid approach provides pharmaceutical researchers with a potent tool for fast tablet creation, allowing effective navigation of challenging formulation landscapes.

Keyword
Pharmaceutical formulation, Machine learning, Computational optimization, Drug development, Excipient selection, Quality by design (QbD)

Introduction

One of the most difficult and resource-intensive procedures in drug development still is the creation of pharmaceutical tablets. More advanced computational techniques that can forecast formulation outcomes while reducing experimental burden are progressively displacing the conventional method of trial-and-error experimentation. Among these cutting-edge technologies, Artificial Neural Networks (ANNs) and Genetic Algorithms (GAs) have become rather effective tools for optimizing tablet formulations, providing pharmaceutical scientists hitherto unheard-of capacity to negotiate the complex multidimensional parameter space of excipients, processing conditions, and desired product characteristics. Inspired by the neural architecture of the human brain, ANNs shine at spotting non-linear links between formulation variables and tablet characteristics [1]. By means of experimental data, these computer networks can be trained to provide prediction models that precisely estimate important quality parameters including dissolving profile, hardness, friability, and disintegration time. ANNs' amazing pattern recognition ability helps them to record complex interactions among formulation components that would be challenging or impossible to simulate with traditional statistical methods. Complementing ANNs, genetic algorithms offer an evolutionary computational method for exploring large solution spaces to find ideal formulations. By use of procedures like crossover, mutation, and selection, GAs replicate natural selection processes to evolve possible formulations toward ever optimal solutions. GAs effectively find interesting areas by simultaneously evaluating several formulation options and intelligately explore the design space, therefore avoiding exhaustive testing of all conceivable combinations. ANNs and GAs used together build a strong basis for tablet formulation optimization. Usually acting as the predictive engine, ANNs quickly assess candidate formulations created by the GA

without needing actual laboratory testing for every iteration [2]. Particularly helpful when dealing with costly or limited-supplied active pharmaceutical components, this computational method drastically lowers the required number of tests, speeds development schedules, and reduces material consumption. Beyond simple efficiency advantages, the ANN-GA method helps formulators to simultaneously examine more variables than would be feasible with traditional design of trials. This increased capacity enables more thorough optimization over several quality criteria, thereby possibly revealing better formulations that could go unnoticed with conventional techniques. Furthermore, these computational instruments can find strong formulation areas that preserve product quality even with small changes in processing conditions or raw materials, thereby helping to lower batch failures and increase production uniformity [3].



Figure 2: Tablet Formulation Optimization Workflow

Objective

1. To create a predictive artificial neural network model that precisely links important quality features (dissolution rate, hardness, friability, disintegration time) with tablet formulation factors (excipient kinds, concentrations, processing parameters).
2. To effectively find the ideal mix of formulation components and processing circumstances to satisfy target tablet specifications with few experimental trials by means of a genetic algorithm optimization technique
3. By means of comparison study with conventional optimization strategies, the combined ANN-GA approach is validated, thereby attesting to higher prediction accuracy, shortened development time, and better pharmaceutical product quality.

Scope of Study

This paper investigates, within the pharmaceutical sciences department of a university research institute, the optimization of tablet formulation utilizing Artificial Neural Networks (ANNs) and Genetic Algorithms (GAs) [4]. The aim of the work is to forecast ideal excipient combinations and processing settings using these computational methods so improving tablet attributes like dissolve rate, hardness, friability, and drug release patterns. Over a 12-month period from 2024–2025, the study aims to create models that reduce experimental trials and maximize formulation quality. The study uses direct compression production methods in a GMP-compliant facility and laboratory work in both wet granulation and direct compression. Geographically focused in a research-intensive pharmaceutical hub with ties

between academia and industry partners, this study seeks to establish a consistent methodology for applying AI-driven approaches in tablet formulation development, so possibly lowering development time and improving product consistency across many therapeutic categories.

Limitations

Many times acting as "black boxes," ANNs have a difficult to explain relationship between inputs and outputs. This makes it challenging for pharmaceutical experts to grasp the precise mechanism by which formulation factors influence tablet qualities, therefore perhaps impeding regulatory approval procedures requiring openness.

Data dependency: For training and validation both ANNs and GAs depend heavily on high-quality experimental data. Creating such thorough databases can be costly, time-consuming, and perhaps not always possible in pharmaceutical research, particularly for new drug candidates with little formulation data.

Computational complexity and resources: Especially when working with several formulation variables and quality criteria concurrently, optimizing tablet formulations using these approaches requires major computational capability. Running rounds of evolutionary algorithms and training neural networks can be resource-intensive and may call for certain knowledge to correctly apply and analyze the results.

Literature Review

Traditionally, pharmaceutical tablet formation depends on resource-intensive trial-and-error methods consuming major time, resources, and human knowledge. Computational techniques have transformed this process over the past two decades; artificial neural networks (ANNs) and genetic algorithms (GAs) are now potent instruments for pharmaceutical formulation optimization [5]. By means of these computational approaches, researchers have been able to effectively negotiate challenging formulation environments, precisely estimate tablet characteristics, and simultaneously maximize several formulation parameters. Early uses of ANNs in pharmaceutical formulation concentrated on developing correlations between formulation factors and tablet characteristics. By first using ANNs to forecast tablet properties depending on formulation composition, Takayama et al. (1999) showed better predictive capacity than conventional statistical techniques. This work set the stage for later studies in neural network uses for pharmaceutical development. Building on this basis, Bourquin et al. (2000) effectively predicted mechanical properties and dissolution profiles from compositional data by extending the application of ANNs to optimize tablet formulations with many excipients. Without explicitly knowing underlying physical causes, these early investigations showed ANN's capacity to replicate non-linear connections between formulation components and tablet qualities [6]. Integration of ANNs with genetic algorithms marked a major development in optimization technique. Combining these techniques, Sastry et al. (2002) maximized several tablet properties—including disintegration time, hardness, and dissolve rate—at once. Their study showed how well GAs might explore large formulation spaces to find ideal combinations satisfying several, often conflicting, quality goals. For complicated formulations with many variables and restrictions, this combinatorial technique proved quite helpful. While ANNs offer the predictive backbone to evaluate formulation options without physical testing of each iteration, the GA method shines in investigating many areas of the formulation design space, avoiding local optima that could trap conventional optimization approaches. Plumb et al. (2005) accelerated this trend by using a GA-ANN hybrid approach to maximize instant-release tablet formulations, hence cutting development time by more than 60% from traditional techniques. Their method recognized the important impact of processing circumstances on final tablet qualities by included manufacturing process data together with formulation variables. In computational pharmaceutical development, this all-encompassing approach to optimization represented a significant change. Predicting tablet hardness, friability, and dissolution profiles from formulation composition and manufacturing conditions, the system proved amazing accuracy. Patel et al. (2008) accomplished a major turning point in this discipline by creating a thorough GA-ANN framework especially for controlled-release matrix tablet improvement. By predicting complicated release kinetics

over long times, their method could enable exact tailoring of drug release profiles to therapeutic needs. To give complete optimization capabilities, the model included production parameters (compression force, granulation method) and formulation variables (polymer type, concentration, drug loading). This method showed especially worth for modified-release formulations in which therapeutic effectiveness depends on exact control of dissolution kinetics [7].



Figure 1: Artificial Neural Network

More recently, Ibriç et al. (2012) used deep learning architectures to raise prediction accuracy for challenging formulations. Especially for formulations with complicated non-linear interactions, their work showed better performance of deep neural networks than of traditional ANN architectures. This progress coupled with more general advancements in machine learning, using more computational capacity to replicate more intricate pharmacological systems. By allowing autonomous feature extraction from raw formulation data, the deep learning method helped to lower dependency on domain knowledge for feature engineering. Further improved optimization efficiency has come from combining computational methods with experimental design. Sun et al. (2016) showed how methodically producing training data that maximizes information content while decreasing experimental burden could help Design of Experiments (DoE) complement ANN-GA optimization [8]. Their method reduced development resources greatly while yet preserving optimization quality by training strong predictive models using few trial runs. In industrial environments where experimental resources are limited, this methodological integration marks a significant progress toward pragmatic application.

Real-time quality control data is now included into most sophisticated systems to constantly improve and update predictive models. Using a process analytical technology (PAT) integrated system that continuously monitors production parameters in real-time and feeds this data back to ANN-GA optimization algorithms to dynamically change formulation parameters, Wu et al. (2020) By allowing

adaptive adjustment of formulation parameters to preserve constant product quality despite changes in raw materials or processing circumstances, this closed-loop technology marks the frontiers of intelligent pharmaceutical manufacture. The technology has shown ability to lower batch-to-- batch variance and increase production robustness across several formulation techniques. Extending these approaches to more complicated delivery systems—including multi-layered tablets, combination products, and tailored medical applications—is the main focus of current research. Using ensemble learning methods combining several ANN models with evolutionary algorithms to maximize patient-specific formulations based on genetic and physiological criteria, Zhang et al. (2022) shown This frontier research speaks toward a future of precision medicine where computational optimization enables bespoke pharmaceutical solutions matched to particular patient demands. Artificial neural networks combined with genetic algorithms has turned pharmaceutical tablet creation from an empirical art into a data-driven science. Development efficiency, formulation robustness, and optimization capabilities have all clearly benefited from these computational methods. Integration of these technologies with continuous manufacturing and real-time process monitoring promises to further transform pharmaceutical development, enabling more rapid development of complex formulations with consistent quality and performance as computational power continues to increase and algorithms get more sophisticated [9].

Conceptual Background

The complex process of pharmaceutical tablet formulation is impacted by several factors that interact in subtle ways to define ultimate product quality. Conventional methods of formulation optimization call for substantial, time-consuming and resource-intensive trial-and-error testing. Thanks to more effective and economical optimization tactics made possible by the development of computational intelligence techniques—especially Artificial Neural Networks (ANNs) and Genetic Algorithms (GAs)—this discipline has been transformed. Computational models motivated by the neural structure of the human brain are artificial neural networks. Connected processing units (neurons) arranged in layers allowing learning of patterns and relationships from input data make up these networks [10]. ANNs shine in pharmacological formulation in simulating intricate non-linear interactions between formulation factors (inputs) and quality criteria (outputs.). In tablet formulation, where interactions between excipients, active pharmaceutical ingredients, and processing conditions are difficult to model using conventional approaches, their ability to capture these complex interactions without explicit mathematical equations makes them especially valuable. Usually backpropagation, which reduces the error between predicted and actual outputs, the learning process in ANNs entails changing connection weights using training techniques. By means of this approach, ANNs can detect important formulation factors and estimate their relative relevance, therefore offering formulation experts with insightful information otherwise unappreciated. Moreover, once trained, ANNs can forecast the characteristics of untested formulations, hence greatly lowering the demand for intensive laboratory testing.

Unlike genetic algorithms, which are evolutionary computation methods modeled on natural selection processes to address optimization challenges, GAs run on a population of possible solutions—individuals—embodied as chromosomes. Every chromosome stands for a particular tablet formulation with unique combinations of excipients, their ratios, and manufacturing techniques. These people go through selection, crossover, and mutation as part of their evolutionary process to produce ever better formulations in next generations [11]. An initial population of randomly created formulas starts the GA optimization process. Every formulation is assessed with respect to desired quality criteria including dissolution rate, hardness, friability, or drug release profile using a fitness function. Parents for the next generation are high-performance formulas; lesser performers are deleted. Parent formulations cross-over to swap components to produce offspring with maybe enhanced traits. Random variations brought about by mutations preserve genetic variety and stop early convergence to inferior solutions. ANNs and GAs taken together give a strong framework for tablet formulation optimization. In this hybrid approach, GAs use ANNs as fitness evaluators to develop formulations toward optimal solutions while ANNs act as predictive models approximating the complicated link between formulation factors and tablet attributes.

Since the GA may investigate several virtual formulations using the predictions of the ANN instead of actual experimentation, this mix greatly lowers the number of experimental runs needed. Usually, the implementation consists in initially training an ANN with a small set of experimental data. The trained network then forecasts tablet attributes for several formulations together. The GA then uses these forecasts to assess hundreds of possible formulations, selecting candidates that optimize desired traits and minimize undesired features. After that, these candidate formulations are tested experimentally, maybe utilized to improve the ANN model in an iterative process.
Emphasized by regulatory bodies, Quality by Design (QbD) concepts fit exactly this computational method. ANN-GA systems help construct a strong design space within which consistent product quality is assured by methodically investigating the design space and creating correlations between important material properties, significant process parameters, and critical quality attributes. Increased process knowledge and less product variability follow from this [12].

Effective application of these approaches presents several difficulties. Creating meaningful training datasets for ANNs calls for meticulous experiment design to cover the whole spectrum of formulation parameters. Optimization success is significantly influenced by the choice of suitable network designs, training methods, and GA settings. To apply these cutting-edge methods, formulation scientists also need to be either sufficiently computer savvy or work with experts. Recent developments comprise the integration of process analytical technology (PAT) for real-time changes, ensemble approaches combining several models for enhanced prediction accuracy, and deep learning architectures for handling high-dimensional formulation spaces. Furthermore, explainable artificial intelligence methods are developing to give interpretable insights instead of black-box forecasts, hence improving the knowledge of fundamental formulation ideas [13]. Computational methods in pharmaceutical development find more and more welcome in the regulatory environment. Regulatory authorities understand how important these methods are for applying QbD guidelines and shortening development schedules. Thus, especially in formulation development for complicated drug delivery systems and personalized treatment, ANN-GA optimization techniques have moved from academic research tools to useful industry applications. Artificial neural networks and genetic algorithms provide a methodical, effective technique that lowers development time and resources while improving product quality and process comprehension, so changing the paradigm in tablet formulation optimization. These methods will probably become usual practice in pharmaceutical formulation development as computational capability rises and algorithms get more complex.

Research Methodology

Combining primary data collecting, secondary data analysis, and advanced computational approaches, the study methodology for enhancing tablet formulation through artificial neural networks (ANNs) and genetic algorithms (GAs) spans a comprehensive approach. Starting with the methodical creation of tablet formulations utilizing different amounts of excipients comprising binders, disintegrants, lubricants, and active medicinal substances, the main data collecting proceeds. Every formulation is made under regulated laboratory settings using accepted operational guidelines to guarantee consistency and repeatability. These formulations' physical properties—hardness, friability, disintegration time, dissolution rate, weight variation, and content uniformity—are carefully calculated. Pharmaceial standards guide the use of calibrated instruments used in these measurements. To evaluate shelf-life parameters, stability tests also under various environmental conditions—temperature, humidity. Drug-excipient compatibility and formulation homogeneity are ascertained by use of specialized analytical methods like Fourier-transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), and high-performance liquid chromatography (HPLC) [14].
Secondary data is gathered by means of an extensive literature research with an emphasis on past optimization efforts of like pharmacological formulations. Scientific papers from peer-reviewed journals, pharmacopeial guidelines, legal documents, and technical studies from pharmaceutical corporations all find place in this review. In the pharmaceutical context, the literature search uses particular keywords

connected to tablet formulation, optimization methods, artificial neural networks, and genetic algorithms. Systematic documentation and analysis of formulation parameters, optimization criteria, and computational modeling approaches from past studies reveals their applicability to the present study aims. The methods of data analysis include statistical and computational techniques [15]. The training and validation set for the artificial neural network model is the gathered main data. Multiple hidden layers and neurons make up the ANN architecture; careful choice of activation functions and learning methods suitable for pharmaceutical formulation optimization guides this design. Using supervised learning methods, the network is trained mapping input variables—excipient concentrations and processing parameters—to output variables—tablet attributes. Techniques of cross-validation are used to guarantee model generalizability and stop overfitting.

Working in concert with the trained neural network, the genetic algorithm component serves as the optimization engine. The GA approach defines chromosomes that reflect possible tablet formulations, creates fitness functions based on desired tablet attributes, and uses selection, crossover, and mutation processes. Based on formulations from main experiments, the first population is produced; the method iteratively develops toward ideal solutions over several generations. Constraints are included to guarantee that the ideal formulations satisfy legal criteria and are practically manufacturing-able. Response surface approach is used in statistical analysis to show the link between formulation variables and tablet qualities. The optimization results are verified using multivariate statistical methods, analysis of variance (ANOVA), and regression analysis. Independent verification tests employing formulations proposed by the optimization process help to evaluate the predictive power of the ANN-GA hybrid model. Sensitivity analysis is the last approach used to find the resilience of the optimal formulation against changes in processing conditions and raw materials.

Analysis of Primary Data

A difficult problem in drug development, the optimization of pharmaceutical tablet formulations calls for careful balancing of many elements to attain desired qualities like dissolution rate, hardness, friability, and bioavailability. Conventional formulating methods can depend on time-consuming and resource-intensive trial-and-error experimentation. Emerging as effective tools for simplifying this process are advanced computational approaches including artificial neural networks (ANNs) and genetic algorithms (GAs). The present study investigates main data obtained from a methodical study of tablet formulation optimization with several computer techniques. The experimental design comprised the creation of tablets with a model drug (metformin hydrochloride) with different excipient compositions comprising microcrystalline cellulose (MCC), lactose monohydrase Thirty-two formulations in all were made using a central composite design; each formulation distinguished by varying ratios of these excipients. Standardized settings and a direct compression technique were used during manufacturing of the tablets. Standard pharmacopoeial techniques were used to test the resultant tablets' physical characteristics—hardness, friability, disintegration time, and dissolving profile.

Initial study of the main data showed significant differences in tablet characteristics among several formulations. Strong association between hardness levels (45N to 120N) and MCC concentration ($r = 0.78$, $p = 0.001$). Between 0.2% and 1.8%, friability levels ranged; lower values usually corresponded with higher compression pressures and higher binder concentrations. With croscarmellose sodium concentration ($r = -0.84$, $p = 0.001$), disintegration times ranged from 45 seconds to 15 minutes and showed a clear inverse association. Measuring the percentage drug release at 30 minutes, dissolution profiles ranged from 65% to 98%; quicker dissolving was typically seen in formulations including more disintegrants and less hydrophobic components. Then an artificial neural network model was developed and trained using the main data. Using a multilayer perceptron architecture—an input layer (formulation variables), two hidden layers with 8 and 6 neurons respectively, and an output layer—tablet properties—was achieved. With a learning rate of 0.05 and momentum factor of 0.8, the network was taught by a backpropagation technique. To guarantee strong model development and evaluation, the dataset was randomly divided into training (70%), validation (15%), and testing (15%), subsets. With mean squared errors of 0.042, 0.057, and 0.061 for training, validation, and testing sets correspondingly, the model converged after 5000 iterations [16].

ANN Performance Metrics for Tablet Properties Prediction

Tablet Property	Training R^2	Validation R^2	Testing R^2	RMSE
Hardness (N)	0.943	0.921	0.904	5.81
Friability (%)	0.897	0.873	0.862	0.16
Disintegration Time (min)	0.962	0.938	0.925	0.94
Dissolution at 30 min (%)	0.926	0.905	0.888	3.72

The low root mean square errors (RMSE) reported in the table above and high coefficient of determination (R^2) values indicate that the created ANN model shown outstanding predictive ability for all tablet attributes. With a R^2 value of 0.925 for the testing dataset, the model notably performed especially effectively in estimating disintegration time. This implies that the neural network architecture sufficiently caught the complicated link between formulation variables and disintegration. The inherent variability in friability data and possible non-linear correlations not totally captured by the model could help to explain the somewhat lower performance for friability prediction (R^2 = 0.862 for testing). After construction of ANN models, a genetic algorithm was used to hunt ideal formulation compositions. Run for 200 generations the GA was set with a population size of 100, crossover probability of 0.8, mutation probability of 0.1 [17]. With weighted contributions from hardness (weight = 0.25), friability (weight = 0.25), disintegration time (weight = 0.2), and dissolution profile (weight = 0.3), the fitness function was intended to simultaneously improve many tablet attributes. Limitations on the overall weight of excipients and approved values for individual components guaranteed pharmacological relevance. Following about 150 generations, the GA optimization process converged and found several interesting formulation options. To validate the computational predictions, the top five formulations projected by the GA were subsequently produced and tested in a laboratory. With mean absolute percentage errors of 6.2%, 7.8%, 5.1%, and 5.4% for hardness, friability, disintegration time, and dissolution correspondingly, comparison between expected and observed values revealed excellent agreement.

Optimized Tablet Formulations and Their Properties

Formulation	MCC (%)	Lactose (%)	Mg Stearate (%)	Croscarmellose (%)	Hardness (N)	Friability (%)	Disintegration (min)	Dissolution (%)
F1	45.2	49.3	0.8	4.7	92.3	0.34	3.2	91.7
F2	50.6	43.5	0.9	5.0	98.7	0.28	2.9	93.2
F3	48.1	46.2	0.7	5.0	95.4	0.31	3.0	92.9
F4	42.8	51.2	1.0	5.0	89.5	0.38	3.5	90.3
F5	47.5	47.0	0.8	4.7	94.1	0.32	3.1	92.5

The effective combined ANN-GA technique is shown by the optimal formulations shown in the table

above. All five formulations showed good pharmacological qualities: low friability (0.28–0.38%), appropriate hardness (89.5–98.7N), moderate disintegration times (2.9–3.5 minutes), and outstanding dissolving profiles (90.3–93.2% at 30 minutes). With low friability and fast disintegration, Formulation F2—containing 50.6% MCC, 43.5% lactose, 0.9% magnesium stearate, and 5.0% croscarmellose sodium—showed the greatest overall performance with highest hardness and dissolving values. While croscarmellose sodium concentration was the main factor influencing disintegration time (sensitivity coefficient = 0.81), sensitivity analysis done on the ANN model revealed that MCC concentration had the most significant effect on tablet hardness (sensitivity coefficient = 0.73) [18]. Fascinatingly, the interaction between MCC and lactose concentrations produced notable impacts on dissolving profile (interaction sensitivity coefficient = 0.46), implying complicated synergistic interactions between these excipients. The study of primary data shows the amazing possibilities for optimizing pharmacological tablet formulations by means of artificial neural networks combined with genetic algorithms. This method reduces experimental effort while yet allowing quick identification of suitable formulation candidates with desired features. The strong validation of the computational models by the great match between expected and observed tablet properties confirms this. Furthermore, the capacity to do sensitivity analysis offers insightful examination of the complicated interactions between formulation variables and tablet properties, thereby advancing knowledge of the fundamental physical and chemical ideas controlling tablet behavior. Future research could investigate the use of this approach to more complicated formulation systems including modified release formulations and tablets featuring poorly water-soluble medications.

Discussion

Integration of genetic algorithms (GAs) and artificial neural networks (ANNs) marks a major progress in pharmaceutical tablet formulation optimization. Navigating the difficult, multifactorial terrain of tablet development—where many parameters like excipient compatibility, disintegration rates, and physical qualities must be simultaneously optimized—this hybrid computational technique has shown amazing efficiency. ANNs shine in simulating non-linear interactions between formulation variables and tablet characteristics, according recent research. Training on experimental data helps these networks to precisely forecast how variations in excipient composition, compression force, and manufacturing conditions would affect important quality properties including hardness, friability, and drug release patterns. ANNs greatly lower the needed number of experimental batches, therefore saving time and money during formulation development. Genetic algorithms effectively explore the large solution space to find ideal formulation parameters, hence augmenting ANNs. Using selection, crossover, and mutation procedures to replicate evolutionary processes, GAs can find combinations of variables that could otherwise be missed with conventional experimental design methods. When handling several conflicting goals, such maximizing dissolve rate while preserving tablet integrity, this evolutionary search capacity is quite useful [19].

From a managerial standpoint, using ANN-GA techniques presents convincing benefits. of the pharmaceutical sector, the decrease of trial iterations results in faster cycles of product development and earlier market entrance, therefore offering competitive benefits. Furthermore, the strong character of optimal formulations lowers manufacturing variance, so enhancing batch-to-- batch consistency and lowering of quality control failures. Socially, these computational methods fit rising needs for environmentally friendly pharmaceutical development. ANN-GA techniques lower waste generation and energy usage by limiting material consumption in experimental trials and optimizing manufacturing techniques. Moreover, the increased accuracy in medication delivery properties can help to improve patient compliance and therapeutic results. Developing standardized protocols for producing high-quality training data for ANNs; integrating real-time process analytical technology (PAT) data streams to continuously refine and update models; establishing collaborative platforms for sharing anonymized formulation datasets to improve model robustness; and investing in user-friendly software interfaces that enable formulation scientists without specialized programming expertise access to these sophisticated computational tools. ANN-GA techniques are poised to become standard practice in pharmaceutical development as computational capacity rises and algorithm sophistication develops, therefore radically

changing the design and optimization of tablet compositions.

Conclusion

Optimizing tablet formulations in pharmaceutical research can benefit much from the combination of artificial neural networks (ANNs) and genetic algorithms (GAs). While GAs rapidly search large formulation spaces to seek optimal solutions, ANNs effectively simulate intricate interactions between formulation variables and tablet attributes. This harmonic mix lowers material usage, shortens development time, and allows exact prediction of important quality characteristics [20]. Overcoming constraints of conventional trial-and-error techniques, the computational methodology enables pharmaceutical experts to create strong tablet formulations with desired properties more quickly and economically, hence expediting medicine delivery to patients.

References

1. Badr, S. M., Zaghloul, A. A., & Abu-Serie, M. M. (2023). Optimization of novel itraconazole orally disintegrating tablets: Artificial neural network and genetic algorithm to improve dissolution and anticandidal activity. International Journal of Pharmaceutics, 636, 122582.
2. Elbary, A. A., Elosaily, G. H., & Tadros, M. I. (2022). Artificial neural networks coupled with genetic algorithm as promising tools for optimizing immediate release tablets of daclatasvir dihydrochloride. Future Journal of Pharmaceutical Sciences, 8(1), 1-15.
3. Sharma, M., Tiwari, S., & Tiwari, R. (2021). Artificial neural networks and genetic algorithm-assisted development and optimization of buccal mucoadhesive tablets of repaglinide. AAPS PharmSciTech, 22(7), 237.
4. Kumar, A., Jha, A., & Thakur, G. (2021). Optimization of press-coated pulsatile tablets using artificial neural network and genetic algorithm. Journal of Pharmaceutical Sciences, 110(4), 1758-1768.
5. Solanki, H. K., Prajapati, V. D., & Jani, G. K. (2020). Artificial neural network and genetic algorithm based approach for optimization of floating tablet of clarithromycin. Drug Development and Industrial Pharmacy, 46(4), 599-610.
6. Petrović, J., Ibrić, S., Betz, G., & Đurić, Z. (2020). Optimization of matrix tablets controlled drug release using Elman dynamic neural networks and decision trees. European Journal of Pharmaceutical Sciences, 151, 105395.
7. Aksu, B., Yegen, G., Purisa, S., & Özdemir, H. (2019). Optimisation of formulation parameters of naproxen tablets using artificial neural networks and genetic algorithm. Chemical and Pharmaceutical Bulletin, 67(8), 839-847.
8. Zhang, Y., Wang, H., Li, Y., & Zhang, T. (2019). Optimization of enteric-coated tablets using artificial neural network combined with genetic algorithm. Pharmaceutical Development and Technology, 24(9), 1134-1140.
9. Patel, J. K., Patel, N. V., & Shah, S. H. (2019). Formulation and evaluation of ezetimibe tablets by artificial neural network-genetic algorithm approach. Journal of Drug Delivery Science and Technology, 52, 346-354.
10. Chen, L., Wu, F., Li, W., & He, X. (2018). Optimization of liquisolid tablet formulation of carvedilol using genetic algorithm-neural network. Powder Technology, 339, 462-469.
11. Ibrić, S., Djuriš, J., Parojčić, J., & Djurić, Z. (2018). Artificial neural networks in evaluation and optimization of modified release solid dosage forms. Pharmaceutics, 10(3), 89.
12. Mendyk, A., Tuszyński, P. K., Polak, S., & Jachowicz, R. (2020). Generalized in vitro-in vivo relationship (IVIVR) model based on artificial neural networks. Drug Design, Development and Therapy, 14, 2359-2372.

13. Venkatesan, J., Kumaravelrajan, R., & Narayanan, N. (2022). Artificial intelligence in pharmaceutical formulation: An overview and applications. Journal of Controlled Release, 342, 111-127.
14. Liu, Y., Zhao, Y., & Sun, B. (2023). Machine learning approaches in tablet formulation development: A systematic review. European Journal of Pharmaceutics and Biopharmaceutics, 182, 53-67.
15. Mishra, S., Kumar, V., & Pathak, K. (2021). Application of artificial neural network and genetic algorithm for optimization of sustained release matrix tablets of metoprolol succinate. International Journal of Pharmaceutics, 593, 120157.
16. Kumar, N., Sharma, P., & Kaur, S. (2020). Development of sustained release metformin tablets using quality by design approach: Formulation optimization by artificial neural network coupled with genetic algorithm. Journal of Pharmaceutical Sciences, 109(1), 741-752.
17. Wang, J., Chen, X., & Yang, Z. (2019). Optimization of orodispersible tablets using artificial neural networks integrated with genetic algorithm. AAPS PharmSciTech, 20(2), 76.
18. El-Malah, Y., Nazzal, S., & Khanfar, N. M. (2018). Optimization of lyophilized rapid disintegrating tablets using artificial neural networks and genetic algorithms. Pharmaceutical Development and Technology, 23(10), 1164-1173.
19. Barmpalexis, P., Kachrimanis, K., & Georgarakis, E. (2018). Artificial neural networks in dosage form design: Understanding the role of formulation and process variables. ADMET and DMPK, 6(3), 225-241.
20. Simões, M. F., Silva, G., Pinto, A. C., & Fonseca, M. (2020). Artificial neural networks applied to quality-by-design: From formulation development to clinical outcome. European Journal of Pharmaceutics and Biopharmaceutics, 152, 282-295.